3.A.1.208.31
Multidrug resistance-associated protein 7, MRP7 or ABCC10 of 1492 aas. Probably involved in cellular detoxification through lipophilic anion extrusion. Isoform 1 is specifically expressed in spleen; isoform 2 is more widely expressed. The combination of ibrutinib and paclitaxel can effectively antagonize ABCB1- and ABCC10-mediated paclitaxel resistance (Zhang et al. 2017). It may function in regulating immune cell infiltration patterns along with four other ABC transporters (ABCA8, ABCA12, ABCB6 and ABCB8) (Wang et al. 2022). In addition to sphingomyelin and ceramide, sugar derivatives of ceramides, hexosylceramides (HexCer), are the major circulating sphingolipids. ABCC10 partakes in modulating the synthesis and subsequent efflux of hexosyl ceramides (HexCer) to HDL in liver cells (Iqbal et al. 2022). Activities of lysosomal ABCC3, ABCC5 and ABCC10 are responsible for
lysosomal sequestration of doxorubicin and paclitaxel-oregongreen488 in
paclitaxel-resistant cancer cell lines (Gronkowska et al. 2023). ABCC10/MRP7 consists of three transmembrane domains and two nucleotide
binding domains. It mediates multidrug resistance of tumor cells to a
variety of anticancer drugs by increasing drug efflux and results in
reducing intracellular drug accumulation (Chen et al. 2024). The transport substrates of
ABCC10/MRP7 include antineoplastic drugs such as taxanes, vinca
alkaloids, and epothilone B, as well as endobiotics such as leukotriene
C4 (LTC4) and estradiol 17 β-D-glucuronide. A variety of
ABCC10/MRP7 inhibitors, including cepharanthine, imatinib, erlotinib,
tariquidar, and sildenafil, can reverse ABCC10/MRP7-mediated MDR.
Additionally, the presence or absence of ABCC10/MRP7 is also closely
related to renal tubular dysfunction, obesity, and other diseases (Chen et al. 2024).
|
| Accession Number: | Q5T3U5 |
|---|
| Protein Name: | Multidrug resistance-associated protein 7 |
|---|
| Length: | 1492 |
|---|
| Molecular Weight: | 161629.00 |
|---|
| Species: | Homo sapiens (Human) [9606] |
|---|
| Number of TMSs: | 17 |
|---|
| Location1 / Topology2 / Orientation3: |
Cell membrane1 / Multi-pass membrane protein2 |
|---|
| Substrate |
vinca alkaloid, paclitaxel, leukotriene, ibrutinib, drug |
|---|
1: MERLLAQLCG SSAAWPLPLW EGDTTGHCFT QLVLSALPHA LLAVLSACYL GTPRSPDYIL
61: PCSPGWRLRL AASFLLSVFP LLDLLPVALP PGAGPGPIGL EVLAGCVAAV AWISHSLALW
121: VLAHSPHGHS RGPLALALVA LLPAPALVLT VLWHCQRGTL LPPLLPGPMA RLCLLILQLA
181: ALLAYALGWA APGGPREPWA QEPLLPEDQE PEVAEDGESW LSRFSYAWLA PLLARGACGE
241: LRQPQDICRL PHRLQPTYLA RVFQAHWQEG ARLWRALYGA FGRCYLALGL LKLVGTMLGF
301: SGPLLLSLLV GFLEEGQEPL SHGLLYALGL AGGAVLGAVL QNQYGYEVYK VTLQARGAVL
361: NILYCKALQL GPSRPPTGEA LNLLGTDSER LLNFAGSFHE AWGLPLQLAI TLYLLYQQVG
421: VAFVGGLILA LLLVPVNKVI ATRIMASNQE MLQHKDARVK LVTELLSGIR VIKFCGWEQA
481: LGARVEACRA RELGRLRVIK YLDAACVYLW AALPVVISIV IFITYVLMGH QLTATKVFTA
541: LALVRMLILP LNNFPWVING LLEAKVSLDR IQLFLDLPNH NPQAYYSPDP PAEPSTVLEL
601: HGALFSWDPV GTSLETFISH LEVKKGMLVG IVGKVGCGKS SLLAAIAGEL HRLRGHVAVR
661: GLSKGFGLAT QEPWIQFATI RDNILFGKTF DAQLYKEVLE ACALNDDLSI LPAGDQTEVG
721: EKGVTLSGGQ RARIALARAV YQEKELYLLD DPLAAVDADV ANHLLHRCIL GMLSYTTRLL
781: CTHRTEYLER ADAVLLMEAG RLIRAGPPSE ILPLVQAVPK AWAENGQESD SATAQSVQNP
841: EKTKEGLEEE QSTSGRLLQE ESKKEGAVAL HVYQAYWKAV GQGLALAILF SLLLMQATRN
901: AADWWLSHWI SQLKAENSSQ EAQPSTSPAS MGLFSPQLLL FSPGNLYIPV FPLPKAAPNG
961: SSDIRFYLTV YATIAGVNSL CTLLRAVLFA AGTLQAAATL HRRLLHRVLM APVTFFNATP
1021: TGRILNRFSS DVACADDSLP FILNILLANA AGLLGLLAVL GSGLPWLLLL LPPLSIMYYH
1081: VQRHYRASSR ELRRLGSLTL SPLYSHLADT LAGLSVLRAT GATYRFEEEN LRLLELNQRC
1141: QFATSATMQW LDIRLQLMGA AVVSAIAGIA LVQHQQGLAN PGLVGLSLSY ALSLTGLLSG
1201: LVSSFTQTEA MLVSVERLEE YTCDLPQEPQ GQPLQLGTGW LTQGGVEFQD VVLAYRPGLP
1261: NALDGVTFCV QPGEKLGIVG RTGSGKSSLL LVLFRLLEPS SGRVLLDGVD TSQLELAQLR
1321: SQLAIIPQEP FLFSGTVREN LDPQGLHKDR ALWQALKQCH LSEVITSMGG LDGELGEGGR
1381: SLSLGQRQLL CLARALLTDA KILCIDEATA SVDQKTDQLL QQTICKRFAN KTVLTIAHRL
1441: NTILNSDRVL VLQAGRVVEL DSPATLRNQP HSLFQQLLQS SQQGVPASLG GP